Information:
Fel:
ID
12005
Beskrivning
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control; ODM derived from: https://clinicaltrials.gov/show/NCT02493322
Länk
https://clinicaltrials.gov/show/NCT02493322
Nyckelord
Versioner (1)
- 31/08/2015 31/08/2015 -
Rättsinnehavare
ODM derived from: https://clinicaltrials.gov/show/NCT02493322
Uppladdad den
31 de agosto de 2015
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Essential Arterial Hypertension NCT02493322
Eligibility Essential Arterial Hypertension NCT02493322
- StudyEvent: Eligibility
Similar models
Eligibility Essential Arterial Hypertension NCT02493322
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
consent
Item
signed consent of the patient;
boolean
C0514044 (UMLS CUI [1])
cardiovascular; participants; hypertension; on treatment; combination; indication; stage; never; high; drug; very
Item
participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the brazilian society of cardiology (2010), who have never been treated and have indication for drug combination treatment.
boolean
C0085580 (UMLS CUI [1])
blood pressure; diagnosis
Item
obs: the diagnosis may be established by previous evaluation of two blood pressure measures ≥ 140/90 mmhg, with two months difference between measurements
boolean
C0857121 (UMLS CUI [1])
clinically significant; investigator; disease; study
Item
patients with any clinically significant disease that in the investigator is opinion can not participate in the study;
boolean
C0012634 (UMLS CUI [1])
blood pressure; randomization; hypertension; diagnosis; screening; visit
Item
secondary hypertension diagnosis or blood pressure above 190x100 mmhg in the screening/randomization visit;
boolean
C0155616 (UMLS CUI [1])
immunocompromised; obesity
Item
morbid obesity or immunocompromised patients;
boolean
C0085393 (UMLS CUI [1])
C0028754 (UMLS CUI [2])
C0028754 (UMLS CUI [2])
diastolic blood pressure; participants; systolic; arms
Item
participants with greater than 10 mmhg difference in the measurements of systolic or diastolic blood pressure between the two arms;
boolean
C3160850 (UMLS CUI [1])
participants; upper
Item
participants who do not have the two upper limbs;
boolean
C1140618 (UMLS CUI [1])
participants
Item
participants with important electrocardiographic changes;
boolean
C0855329 (UMLS CUI [1])
creatinine clearance
Item
creatinine clearance - less than 60 ml /min;
boolean
C0373595 (UMLS CUI [1])
cardiovascular; moderate; severe; events
Item
history of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months;
boolean
C1561291 (UMLS CUI [1])
microalbuminuria; urine
Item
microalbuminuria in urine sample greater than 30 mg/g;
boolean
C0730345 (UMLS CUI [1])
history of hypersensitivity to mistletoe
Item
patients with history of hypersensitivity to any of the formula compounds;
boolean
C0020517 (UMLS CUI [1])
pregnancy
Item
pregnancy or risk of pregnancy and lactating patients;
boolean
C2828358 (UMLS CUI [1])
C0549206 (UMLS CUI [2])
C0549206 (UMLS CUI [2])
clinical trial; study; year
Item
participation in clinical trial in the year prior to this study.
boolean
C0008976 (UMLS CUI [1])